Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 + BCG in High Risk Superficial Bladder Cancer
NCT02324582Phase 1Completed
- Sponsor
- Southern Illinois University
- Start
- Jun 2015
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Southern Illinois University. Primary endpoint: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events at 23 weeks. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02324582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324582.